BACKGROUND: In 2003 an estimated 37,500 of Scotland's population was chronically infected with HCV; 44% were undiagnosed former injecting drug users (IDU)--a priority group for antiviral therapy. AIM: To evaluate a hepatitis C virus (HCV) screening intervention. DESIGN: Outcome measures among two similar General Practice populations in an area of high HCV and drug use prevalence, one of which was exposed to an HCV screening intervention, were compared. METHODS: Thirty to fifty four year old attendees of the intervention practice were opportunistically offered testing and counselling, where clinically appropriate, (November 2003-April 2004). OUTCOMES: HCV test uptake, case detection, referral and treatment administration rates. RESULTS: Of 584 eligible attendees, 421 (72%) were offered and 117 (28%) accepted testing in the intervention practice; no testing was undertaken in the comparison practice. Prevalences of HCV antibody were 13% (15/117), 75% (3/4) and 91% (10/11) among all tested persons, current IDUs and former IDUs respectively. For 4/15 (27%) evidence of binge drinking following the receipt of their positive result, was available. Of the 11 referred to specialist care because they were HCV RNA positive, nine attended at least one appointment. Two received treatment: one had achieved a sustained viral response as of February 2008. CONCLUSION: While non targeted HCV screening in the general practice setting can detect infected former IDU, the low diagnostic yield among non IDUs limited the effectiveness of the intervention. A more targeted approach for identifying former IDUs is recommended. Additionally, the low uptake of treatment among chronically infected persons four years after diagnosis demonstrates the difficulties in clinically managing such individuals. Strategies, including support for those with a history of problem alcohol use, to improve treatment uptake are required.
BACKGROUND: In 2003 an estimated 37,500 of Scotland's population was chronically infected with HCV; 44% were undiagnosed former injecting drug users (IDU)--a priority group for antiviral therapy. AIM: To evaluate a hepatitis C virus (HCV) screening intervention. DESIGN: Outcome measures among two similar General Practice populations in an area of high HCV and drug use prevalence, one of which was exposed to an HCV screening intervention, were compared. METHODS: Thirty to fifty four year old attendees of the intervention practice were opportunistically offered testing and counselling, where clinically appropriate, (November 2003-April 2004). OUTCOMES: HCV test uptake, case detection, referral and treatment administration rates. RESULTS: Of 584 eligible attendees, 421 (72%) were offered and 117 (28%) accepted testing in the intervention practice; no testing was undertaken in the comparison practice. Prevalences of HCV antibody were 13% (15/117), 75% (3/4) and 91% (10/11) among all tested persons, current IDUs and former IDUs respectively. For 4/15 (27%) evidence of binge drinking following the receipt of their positive result, was available. Of the 11 referred to specialist care because they were HCV RNA positive, nine attended at least one appointment. Two received treatment: one had achieved a sustained viral response as of February 2008. CONCLUSION: While non targeted HCV screening in the general practice setting can detect infected former IDU, the low diagnostic yield among non IDUs limited the effectiveness of the intervention. A more targeted approach for identifying former IDUs is recommended. Additionally, the low uptake of treatment among chronically infected persons four years after diagnosis demonstrates the difficulties in clinically managing such individuals. Strategies, including support for those with a history of problem alcohol use, to improve treatment uptake are required.
Authors: Joanne E Brady; Danielle K Liffmann; Anthony Yartel; Natalie Kil; Alex D Federman; Joseph Kannry; Cynthia Jordan; Omar I Massoud; David R Nerenz; Kimberly A Brown; Bryce D Smith; Claudia Vellozzi; David B Rein Journal: Hepatology Date: 2016-11-25 Impact factor: 17.425
Authors: Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins Journal: BMC Public Health Date: 2014-01-22 Impact factor: 3.295
Authors: Esther Jane Aspinall; Joseph Samuel Doyle; Stephen Corson; Margaret Elena Hellard; David Hunt; David Goldberg; Tim Nguyen; Yngve Falck-Ytter; Rebecca Lynn Morgan; Bryce Smith; Mark Stoove; Stefan Zbyszko Wiktor; Sharon Hutchinson Journal: Eur J Epidemiol Date: 2014-11-11 Impact factor: 8.082
Authors: Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi Journal: J Viral Hepat Date: 2019-08-16 Impact factor: 3.728
Authors: A McLeod; S J Hutchinson; A Weir; S Barclay; J Schofield; C Gillespie Frew; D J Goldberg; M Heydtmann; E Wilson-Davies Journal: Epidemiol Infect Date: 2022-06-27 Impact factor: 4.434
Authors: Sabrina A Assoumou; Abriana Tasillo; Jared A Leff; Bruce R Schackman; Mari-Lynn Drainoni; C Robert Horsburgh; M Anita Barry; Craig Regis; Arthur Y Kim; Alison Marshall; Sheel Saxena; Peter C Smith; Benjamin P Linas Journal: Clin Infect Dis Date: 2018-01-18 Impact factor: 20.999
Authors: Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar Journal: BMC Infect Dis Date: 2013-04-18 Impact factor: 3.090